Results 71 to 80 of about 3,535 (191)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency

, 2015
Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability.
Bamberger, Mitchell H., Lee, Raymond, Ellsworth, Pamela   +2 more
core   +1 more source

Exploratory analysis of the effect of mirabegron on urodynamic sensation parameters and urethral pressure variations

, 2020
Introduction and hypothesis Urethral instability (URI) has in the past been defined by the International Continence Society (ICS), but was excluded from ICS terminology and definitions shortly after because of a lack of consensus about the clinical ...
Elzevier, H.W., Kummeling, M.T.M., Koeveringe, G.A. van, Putter, H., van Koeveringe, G.A., Groenendijk, P.M., Egberts, J.   +6 more
core   +1 more source

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

BMC Urology, 2018
Background Persistence on-treatment with antimuscarinics in patients with overactive bladder (OAB) is reported to be sub-optimal. This retrospective, longitudinal, observational cohort study assessed treatment persistence with β3-adrenoceptor agonists (i.
Jameel Nazir, Zalmai Hakimi, Florent Guelfucci, Amine Khemiri, Francis Fatoye, Ana María Mora Blázquez, Marta Hernández González   +6 more
doaj   +1 more source

Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study

Neurourology and Urodynamics, Volume 45, Issue 7, Page 1319-1327, September 2026.
ABSTRACT Introduction Intravesical oxybutynin (IVO) is a 2nd line treatment option for patients with neurogenic detrusor overactivity (NDO) who are not adequately managed by oral anticholinergics. The UPSIDE study aimed to identify urodynamic and anamnestic predictors for achieving a therapeutically satisfactory dose (TSD) of 1 mg/mL IVO and to ...
Arndt Van Ophoven, Severine Banek, Kristin Becker, Markus Heibel, Almut Hirsch, Margot Kieruj, Ines Kurze, Anja Lingnau, Barbara Ludwikowski, Tobias Luithle, Fabian Queissert, Wolfgang Rösch, Oliver Schindler, Regina Stredele, Thomas Michael Karl Völkl, Quentin Leidl, Michael Gedamke   +16 more
wiley   +1 more source

Prior Authorization for Sacral Nerve Stimulation in the Era of WISeR: Evaluation of U.S. Payer Coverage Policies

Neurourology and Urodynamics, Volume 45, Issue 7, Page 1280-1293, September 2026.
ABSTRACT Introduction Sacral nerve stimulation (SNS) is an established therapy for refractory urinary incontinence, yet the 2025 Wasteful and Inappropriate Service Reduction Model (WISeR) designated it as requiring mandatory prior authorization. No analysis has examined how U.S.
Thriaksh Rajan, Andre Revnew, David Sheyn, Adonis Hijaz, Ramy Abou Ghayda   +4 more
wiley   +1 more source

Can mirabegron facilitate ureteral access sheath placement during flexible ureterorenoscopy?

, 2020
Aim: In this study, we aimed to demonstrate the effect of mirabegron on ureteral access sheath (UAS) placement during flexible ureterorenoscopy (f-URS)
Karadag, Mert Ali, Keske, Murat, SÖNMEZ, GÖKHAN   +2 more
core   +1 more source

Efficacy and Safety of Mirabegron Compared to Solifenacin in Treatment of Non-neurogenic Overactive Bladder in Children: A Randomized Controlled Trial [PDF]

International Brazilian Journal of Urology
Purpose: Non-neurogenic overactive bladder (OAB) is a common problem in children. Antimuscarinics have been widely used as first-line medical treatment. However, their frequent side effects necessitate searching for therapeutic alternatives.
Islam Mansour, Mahmoud Laymon, Ahmed Abdelhalim, Mohamed S. Dawaba, Ahmed S. El-Hefnawy   +4 more
doaj   +1 more source

The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among Hospitalised Older Patients

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 3, September 2026.
ABSTRACT Introduction 37%–48% of older patients receive anticholinergic medicines, increasing the risk for falls, delirium, dementia and death. Hospital admission may provide an opportunity for deprescribing to improve outcomes. This study evaluated the feasibility and acceptability of a digital tool to identify anticholinergic medicines and support ...
Kinda Ibrahim, Eloise Radcliffe, Edward Hewertson, Andrew Bates, Andy Fox, Emily Smith, Cathrine Mckenzie, Liam Jones, Sara Mckelvie, Ngianga Ii Kandala, Sara McCloskey, Tracey Sach, Stephen Lim   +12 more
wiley   +1 more source

Mirabegron – a selective ß3-adrenoreceptor agonist for the treatment of overactive bladder

, 2012
Alka A Bhide, G Alessandro Digesu, Ruwan Fernando, Vik KhullarDepartment of Urogynaecology, St Mary's Hospital, London, United KingdomAbstract: Overactive bladder is a common condition that significantly impacts overall quality of life ...
Khullar V, Digesu GA, Fernando R, Bhide AB   +3 more
core  

Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder. [PDF]

, 2012
15.04.14 KB. Ok to add published version to Spiral, OA paperOveractive bladder is a common condition that significantly impacts overall quality of life.
Digesu, GA, Fernando, R, Khullar, V, Bhide, AA   +3 more
core   +1 more source